EXPERIMENTAL NEUROLOGY is a premier academic journal published by Academic Press Inc, Elsevier Science, focusing on advancements in the fields of Developmental Neuroscience and Neurology. With an impressive Impact Factor and ranked in the Q1 quartile of both categories—positioning it among the top-tier journals—this publication has established itself as a vital resource for researchers, clinicians, and students alike. Since its inception in 1959, it has fostered the dissemination of cutting-edge research and innovative approaches to understanding neurological function and related disorders. While EXPERIMENTAL NEUROLOGY currently operates under a subscription access model, its rich archives and ongoing contributions to the field continue to inspire and inform the next generation of neurobiologists. The journal also boasts a high ranking in Scopus, placing fourth in Developmental Neuroscience and twentieth in Neurology, indicating its robust influence and scholarly significance. For those committed to advancing knowledge in these critical areas, EXPERIMENTAL NEUROLOGY is an indispensable platform for inquiry and discovery.

Translational Neurodegeneration, an esteemed journal in the field of neuroscience, is published by BMC and has been an open access platform since 2012, delivering high-quality research from its base in the United Kingdom. With an impressive impact factor reflecting its significant contributions, this journal focuses on critical advancements in cellular and molecular neuroscience, cognitive neuroscience, and clinical neurology, boasting a Q1 ranking across all these categories as of 2023. Researchers and professionals benefit from its extensive reach, characterized by exceptional Scopus rankings that place it in the top percentile of its field. The journal serves as a vital resource for academics and healthcare practitioners alike, aiming to bridge the gap between laboratory discoveries and clinical applications, thereby enhancing understanding and treatment of neurodegenerative diseases. With its commitment to open access, Translational Neurodegeneration ensures that its published research is accessible to a global audience, promoting collaboration and knowledge exchange within the scientific community.

NEUROCHEMISTRY INTERNATIONAL, published by Pergamon-Elsevier Science Ltd, offers a premier platform for researchers and professionals in the realms of cell biology and cellular and molecular neuroscience. Established in 1980 and continuing its passion for advancing the field, this esteemed journal enhances scientific collaboration with a notable 2023 Q2 ranking in both relevant categories, placing it among the top-tier publications in its discipline with a Scopus rank of 23/97 for Cellular and Molecular Neuroscience. With its focus on groundbreaking research, the journal provides a wealth of vital data and insights that drive forward our understanding of neurochemistry and its implications in health and disease. While not an Open Access journal, NEUROCHEMISTRY INTERNATIONAL is integral for professionals, academics, and students aiming to stay at the forefront of neurobiological research innovations, making significant contributions to both academia and clinical applications.

Neurochemical Journal, published by MAIK NAUKA/INTERPERIODICA/SPRINGER, focuses on the dynamic and rapidly evolving field of neurochemistry, providing insights into cellular and molecular neuroscience. Despite the discontinuation of its coverage in Scopus, the journal remains a valuable resource for researchers and professionals seeking to explore the biochemical underpinnings of neural function and pathophysiology. With an ISSN of 1819-7124 and an E-ISSN of 1819-7132, the journal aims to publish rigorous research articles, reviews, and notes that push the boundaries of our understanding of neurochemical processes. With a ranking that places its subjects in the lower quartile of their respective fields, Neurochemical Journal offers a platform for innovative studies and discussions among up-and-coming scientists, making it a crucial outlet for advancing the discourse in this critical area of biomedical research.

Frontiers in Cellular Neuroscience, published by FRONTIERS MEDIA SA, is an esteemed open-access journal operating out of Switzerland that has been at the forefront of disseminating cutting-edge research since its inception in 2007. With a focus on the cellular and molecular aspects of neuroscience, this journal addresses fundamental questions and advances our understanding of the nervous system, making it indispensable for researchers, professionals, and students in the field. As of 2023, it is ranked in the Q2 category for Cellular and Molecular Neuroscience, positioned at rank #27 out of 97 in Scopus, and boasting a notable 72nd percentile ranking, reflecting its impactful contributions to the discipline. The journal's commitment to open access enhances the accessibility of vital research findings, promoting knowledge sharing and collaboration. Researchers looking for a platform to publish groundbreaking neuroscience research will find Frontiers in Cellular Neuroscience an ideal venue for reaching a wide audience.

NEUROREPORT is a distinguished journal in the field of neuroscience, published by Lippincott Williams & Wilkins. With an ISSN of 0959-4965 and an E-ISSN of 1473-558X, the journal has established itself as a vital platform for disseminating innovative research and developments in the dynamic area of neuroscience since its inception in 1990. Currently, it is positioned in the Q3 category of the 2023 Journal Rankings, reflecting its respectable standing within the community of neuroscience professionals, ranked #74 out of 113 in general neuroscience on Scopus, placing it in the 34th percentile. While it operates on a traditional subscription model, NEUROREPORT is committed to fostering knowledge sharing in the realm of neurobiology, neuropharmacology, and cognitive studies among researchers, professionals, and students alike. With its broad scope and commitment to scientific excellence, the journal continues to be a cornerstone for those seeking to stay ahead in the evolving landscape of neurological research.

The Journal of Neuroimmune Pharmacology, published by Springer, is a premier academic journal dedicated to advancing the field of pharmacology intersecting with neuroscience and immunology. With an outstanding impact factor and proudly positioned in the Q1 quartile across multiple categories, this journal showcases cutting-edge research that enhances our understanding of the neuroimmune system and its pharmacological implications. Established in 2006 and continuing through 2024, it serves as a vital resource for researchers, professionals, and students alike, offering insights into the mechanisms of drug action, disease processes, and therapeutic strategies. As a testament to its excellence, the journal ranks prominently in Scopus metrics within its discipline, making it an essential platform for disseminating high-quality research that drives innovation in immunology, allergy, neuroscience, and pharmacology.

ASN Neuro is an esteemed academic journal published by Frontiers Media SA, focusing on critical advancements in the fields of neurology and neuroscience. Since its inception in 2009, it has established itself as an Open Access platform dedicated to fostering the dissemination of knowledge and research findings that address the complexities of the nervous system. With an impressive impact factor and consistently ranking in the top quartiles of its categories—Q1 in Neurology (clinical) and Q2 in Neuroscience (miscellaneous)—ASN Neuro is recognized for its high-quality publications that cater to the evolving challenges in clinical neurology and general neuroscience. Currently, it ranks 68th out of 400 journals in Clinical Neurology and 28th out of 113 in General Neuroscience, affirming its reputable position within the academic community. Researchers, professionals, and students alike are encouraged to contribute to and benefit from this impactful journal as it presents a unique opportunity to engage with cutting-edge research, innovative methodologies, and insightful reviews in the ever-evolving landscape of brain science.

eNeuro is a prominent open-access journal published by the Society for Neuroscience, dedicated to advancing the field of neuroscience through the dissemination of high-quality research. Launched in 2015, it reflects its commitment to accessibility by providing a platform for innovative studies and advancements in neurobiology. The journal holds a strong reputation, achieving a Q1 ranking in Medicine (miscellaneous) and a Q2 in Neuroscience (miscellaneous) as of 2023, with Scopus rankings placing it at #56 out of 113 in General Neuroscience, marking it in the 50th percentile. With its convergence to cover articles from 2014 to 2024, eNeuro continues to serve as a vital resource for researchers, professionals, and students alike, offering a comprehensive hub for the latest discoveries and theoretical developments in neuroscience. As part of its mission, eNeuro aims to foster collaboration and inspire the academic community with openly accessible content, making significant contributions to scientific discourse.

Neurotrauma Reports, published by MARY ANN LIEBERT, INC, stands at the forefront of disseminating pivotal research within the evolving field of neuroscience. With an emphasis on both cellular and molecular neuroscience and developmental neuroscience, this open access journal, initiated in 2020, aims to bridge gaps in knowledge concerning neurotrauma, a critical area impacting brain health and recovery. Although currently positioned in the lower quartiles as per the 2023 category rankings, the journal provides invaluable insights that foster academic dialogue and collaboration among researchers, professionals, and students alike. Through its commitment to open access, Neurotrauma Reports ensures that cutting-edge research is accessible to a diverse audience, enhancing the visibility of emerging studies and fostering innovation within the field. Readers can explore this journal to stay updated with the latest findings, methodologies, and reviews that are shaping our understanding of neurotrauma, ultimately contributing to improved treatments and outcomes.